EV71 vaccines: A first step towards multivalent hand, foot and mouth disease vaccines

Expert Review of Vaccines

Volumn 14, Issue 3, 2015, Pages 337-340

  Klein, Michel H ^a  

^a VaxiBio Inc   (Canada)

Author keywords

coxsackieviruses A16, A6, A10; cross neutralizing antibody; Enterovirus 71; hand foot and mouth diseases; human enteroviruses A; vaccines

Indexed keywords

EV71 VACCINE; INACTIVATED VIRUS VACCINE; UNCLASSIFIED DRUG; INACTIVATED VACCINE; VIRUS VACCINE;

COXSACKIE VIRUS A; COXSACKIE VIRUS INFECTION; ECHO VIRUS; ENTEROVIRUS 71; HAND FOOT AND MOUTH DISEASE; HUMAN; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; REVIEW; ASIA; DRUG DEVELOPMENT; ENTEROVIRUS; ENTEROVIRUS A; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; PACIFIC ISLANDS; PRESCHOOL CHILD; PROCEDURES; TRENDS; VACCINATION;

ASIA; CHILD, PRESCHOOL; DRUG DISCOVERY; ENTEROVIRUS; ENTEROVIRUS A, HUMAN; HAND, FOOT AND MOUTH DISEASE; HUMANS; INFANT; PACIFIC ISLANDS; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84923070523     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.993385     Document Type: Review

References (24)

1. Solomon T, Lewthwarte P, Perera D, et al. Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect Dis 2010;10(11):778-90
2. Yip CCY, Lau SKP, Woo PCY, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J 2013;6:19780
3. Mao Q, Wang Y, Yao X, et al. Coxsackievirus A16: epidemiology, diagnosis and vaccine. Hum Vaccin Immunother 2014;10(2):360-7
4. Cheng A, Fung CP, Liu CC, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013;31: 2471-6
5. Zhu PC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvanted enterovirus 71 vaccine in children in Mainland China: a multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet 2013;381(9882): 2024-32
6. Zhu F, Xu W, Xia J, et al. Efficacy safety and immunogenicity of an enterovirus 71 vaccine in Mainland China. N Engl J Med 2014;370(9):818-28
7. Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014;370(9):829-37
8. Liu CC, Chow YH, Chong P, Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine 2014. [Epub ahead of print]
9. Kung YA, Hung CT, Liu YC, Shih SR. Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther 2014; 14(10):1455-64
10. Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in Mainland China, 2008-12: an epidemiological study. Lancet Infect Dis 2014;14(4):308-18
11. Chong P, Hsieh SY, Liu CC, et al. Production of EV71 vaccine candidates. Hum Vaccin Immunother 2012;8(12): 1775-83
12. Chou AH, Liu CC, Chang JY, et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol 2012;831282
13. Chou AH, Liu CC, Chang JY, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody responses against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013;8(11):e79783
14. Shenyu W, Jingxin L, Zhenglun L, et al. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized. double-blind, placebo-controlled clinical trial. J Infect Dis 2014;210(7):1073-82
15. Han JF, Cao RY, Deng YQ, et al. Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo. Virol J 2011;8:106-13
16. Lin CW, Liu CC, Lu TC, et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. Biomed Res Int 2014;670506
17. Chen JF, Zhang RS, Ou XH, et al. The role of enterovirus 71 and coxsackievirus A strains in a large outbreak of hand, foot and mouth disease in 2012 in Changsha, Mainland China. Int J Infect Dis 2014;28C:17-25
18. Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand, foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010;14(12):e1076-81
19. Lu QB, Zhang XA, Wo Y, et al. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in Mainland China, 2009-2011. PLoS One 2012;7(12): e52073
20. Di B, Zhang Y, Xie H, et al. Circulation of Coxsackievirus A6 in hand-foot-mouth disease in Guanzhou, 2010-2012. Virol J 2014;11:157-63
21. Mirand A, Henquell C, Archimbaud C, et al. Outbreak of hand foot and mouth disease/herpangina associated with coxsackie A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect 2012;18(5): E110-18
22. Wang YF, Yu CK. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 2014;21:31-41
23. Lin YW, Yu SL, Shao H, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 2013;8(2):e57591
24. Lee BY, Wateska A, Bailey RR, et al. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine 2010;28(49):7731-6